Tharimmune Inc
THAR2.320USD
+0.100+4.50%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
16.72MMarket Cap
LossP/E TTM
More Details of Tharimmune Inc Company
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.
Tharimmune Inc Info
Ticker SymbolTHAR
Company nameTharimmune Inc
IPO dateJan 12, 2022
CEOWendland (Mark Paul)
Number of employees2
Security typeOrdinary Share
Fiscal year-endJan 12
Address1200 Route 22 East
CityBRIDGEWATER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08807
Phone13027432995
Websitehttps://tharimmune.com/
Ticker SymbolTHAR
IPO dateJan 12, 2022
CEOWendland (Mark Paul)
Company Executives of Tharimmune Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sireesh Appajosyula
Mr. Sireesh Appajosyula
Chief Executive Officer of Gravitas Life Sciences, Director
Chief Executive Officer of Gravitas Life Sciences, Director
61.59K
-1.11%
Mr. Vincent Lopriore
Mr. Vincent Lopriore
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Clay Kahler
Mr. Clay Kahler
Independent Director
Independent Director
--
--
Mr. Gary Stetz
Mr. Gary Stetz
Independent Director
Independent Director
--
--
Mr. Mark Toomey
Mr. Mark Toomey
President
President
--
--
Mr. Mark Wendland
Mr. Mark Wendland
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. James Gordon Liddy
Mr. James Gordon Liddy
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sireesh Appajosyula
Mr. Sireesh Appajosyula
Chief Executive Officer of Gravitas Life Sciences, Director
Chief Executive Officer of Gravitas Life Sciences, Director
61.59K
-1.11%
Mr. Vincent Lopriore
Mr. Vincent Lopriore
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Clay Kahler
Mr. Clay Kahler
Independent Director
Independent Director
--
--
Mr. Gary Stetz
Mr. Gary Stetz
Independent Director
Independent Director
--
--
Mr. Mark Toomey
Mr. Mark Toomey
President
President
--
--
Mr. Mark Wendland
Mr. Mark Wendland
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gravitas Capital LP
2.69%
BlackRock Institutional Trust Company, N.A.
1.89%
Evelyn Rickel Trust FBO Kenneth D. Rickel
1.72%
GSB Holdings, Inc.
0.96%
SDS Capital Partners, LLC
0.90%
Other
91.83%
Shareholders
Shareholders
Proportion
Gravitas Capital LP
2.69%
BlackRock Institutional Trust Company, N.A.
1.89%
Evelyn Rickel Trust FBO Kenneth D. Rickel
1.72%
GSB Holdings, Inc.
0.96%
SDS Capital Partners, LLC
0.90%
Other
91.83%
Shareholder Types
Shareholders
Proportion
Corporation
6.36%
Investment Advisor
2.13%
Individual Investor
0.99%
Hedge Fund
0.90%
Investment Advisor/Hedge Fund
0.13%
Research Firm
0.03%
Other
89.46%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
25
1.12M
3.41%
+940.88K
2025Q2
32
1.13M
24.46%
+528.63K
2025Q1
29
348.52K
13.93%
+147.24K
2024Q4
27
187.29K
9.69%
+110.78K
2024Q3
26
45.46K
4.30%
-11.51K
2024Q2
28
20.34K
2.37%
-27.10K
2024Q1
31
18.55K
2.14%
-25.77K
2023Q4
29
23.24K
19.49%
-10.54K
2023Q3
30
18.10K
45.22%
-4.20K
2023Q2
30
21.56K
66.00%
+3.49K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gravitas Capital LP
944.42K
13.87%
+212.00K
+28.94%
Aug 26, 2025
Evelyn Rickel Trust FBO Kenneth D. Rickel
603.00K
8.86%
+603.00K
--
Aug 26, 2025
GSB Holdings, Inc.
335.51K
4.93%
+168.92K
+101.40%
Aug 26, 2025
SDS Capital Partners, LLC
315.88K
4.64%
+315.88K
--
Aug 26, 2025
Brightforge Management, LLC
295.09K
4.33%
+295.09K
--
Aug 26, 2025
Clarke (David Howard)
174.98K
2.57%
+139.98K
+399.94%
Aug 26, 2025
Stetz (Gary S)
101.35K
1.49%
--
--
Aug 26, 2025
Appajosyula (Sireesh)
61.59K
0.9%
-690.00
-1.11%
Aug 26, 2025
Bounty Hunter LLC
47.60K
0.7%
--
--
Aug 26, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 23, 2024
Merger
15→1
May 23, 2024
Merger
15→1
May 23, 2024
Merger
15→1
May 23, 2024
Merger
15→1
Nov 17, 2023
Merger
25→1
Nov 17, 2023
Merger
25→1
Date
Type
Ratio
May 23, 2024
Merger
15→1
May 23, 2024
Merger
15→1
May 23, 2024
Merger
15→1
May 23, 2024
Merger
15→1
Nov 17, 2023
Merger
25→1
Nov 17, 2023
Merger
25→1
Nov 17, 2023
Merger
25→1
Nov 17, 2023
Merger
25→1
FAQs
Who are the top five shareholders of Tharimmune Inc?
The top five shareholders of Tharimmune Inc are:
Gravitas Capital LP holds 944.42K shares, accounting for 13.87% of the total shares.
Evelyn Rickel Trust FBO Kenneth D. Rickel holds 603.00K shares, accounting for 8.86% of the total shares.
GSB Holdings, Inc. holds 335.51K shares, accounting for 4.93% of the total shares.
SDS Capital Partners, LLC holds 315.88K shares, accounting for 4.64% of the total shares.
Brightforge Management, LLC holds 295.09K shares, accounting for 4.33% of the total shares.
Gravitas Capital LP holds 944.42K shares, accounting for 13.87% of the total shares.
Evelyn Rickel Trust FBO Kenneth D. Rickel holds 603.00K shares, accounting for 8.86% of the total shares.
GSB Holdings, Inc. holds 335.51K shares, accounting for 4.93% of the total shares.
SDS Capital Partners, LLC holds 315.88K shares, accounting for 4.64% of the total shares.
Brightforge Management, LLC holds 295.09K shares, accounting for 4.33% of the total shares.
What are the top three shareholder types of Tharimmune Inc?
The top three shareholder types of Tharimmune Inc are:
Gravitas Capital LP
BlackRock Institutional Trust Company, N.A.
Evelyn Rickel Trust FBO Kenneth D. Rickel
Gravitas Capital LP
BlackRock Institutional Trust Company, N.A.
Evelyn Rickel Trust FBO Kenneth D. Rickel
How many institutions hold shares of Tharimmune Inc (THAR)?
As of 2025Q3, 25 institutions hold shares of Tharimmune Inc, with a combined market value of approximately 1.12M, accounting for 3.41% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -21.05%.
What is the biggest source of revenue for Tharimmune Inc?
In --, the -- business generated the highest revenue for Tharimmune Inc, amounting to -- and accounting for --% of total revenue.
